GlassScriptPhysician profile
Albert Tartini
NPI 1346240298
$2,070.52
in general payments reported to CMS, 2019-2025
22 companies · $360 in 2025
The $360 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $518 · 2020: $215 · 2021: $228 · 2022: $111 · 2023: $239 · 2024: $400 · 2025: $360.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $959 · Education: $39.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $959.27 |
| Education | $39.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $306.30 | 2019-2024 | Veltassa, Korsuva |
| Amgen INC. | $241.87 | 2019-2024 | Tavneos, Krystexxa, Aranesp |
| Novartis Pharmaceuticals Corporation | $241.33 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $240.89 | 2019-2025 | Jynarque |
| Akebia Therapeutics INC | $174.63 | 2019-2025 | Vafseo, Auryxia |
| Medtronic, INC. | $156.96 | 2025 | Ellipsys Vascular Access System |
| Opko Pharmaceuticals, LLC | $152.42 | 2019-2023 | Rayaldee |
| Fresenius USA Marketing, INC. | $132.23 | 2019-2025 | Velphoro, Velphoro |
| Travere Therapeutics, INC. | $73.09 | 2024-2025 | |
| Calliditas Therapeutics US INC. | $57.57 | 2022-2025 | Tarpeyo |
| Bayer Healthcare Pharmaceuticals INC. | $56.42 | 2021-2023 | |
| Ardelyx, INC. | $30.20 | 2024-2025 | Ibsrela |
| Mallinckrodt Hospital Products INC. | $28.13 | 2020-2021 | |
| Glaxosmithkline, LLC. | $27.89 | 2020-2022 | |
| Horizon Therapeutics Plc | $26.71 | 2019-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $24.38 | 2019 | |
| Recor Medical INC | $21.94 | 2024 | Paradise Renal Denervation System |
| Janssen Biotech, INC. | $19.16 | 2019 | |
| Mallinckrodt Enterprises LLC | $17.30 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.99 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $13.61 | 2024 | Farxiga |
| Esperion Therapeutics, INC. | $12.50 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Tartini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.